Do analysts recommend NLTX or GLUE?

Monte Rosa Therapeutics has a consensus price target of $28.50, suggesting a potential upside of 83.87%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts recommend NLTX or AKTS?

Aktis Oncology has a consensus price target of $34.60, indicating a potential upside of 38.79%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aktis Oncology 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Is NLTX or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Aktis Oncology N/A N/A N/A

Do analysts prefer NVAX or NLTX?

Novavax presently has a consensus price target of $13.00, indicating a potential upside of 61.49%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novavax 3 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.20 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend IMTX or NLTX?

Immatics presently has a consensus target price of $20.80, indicating a potential upside of 120.34%. Given Immatics' stronger consensus rating and higher possible upside, analysts clearly believe Immatics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend NLTX or VOR?

Vor Biopharma has a consensus price target of $43.38, suggesting a potential upside of 88.34%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vor Biopharma 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82

Which has higher earnings & valuation, NLTX or VOR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is NLTX or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Vor Biopharma N/A N/A N/A

Neoleukin Therapeutics (NLTX) Competitors

$35.63 -1.35 (-3.65%)

As of 08/13/2026

Compare

NLTX vs. GLUE, AKTS, NVAX, IMTX, and VOR

Should you buy Neoleukin Therapeutics stock or one of its competitors? Neoleukin Therapeutics's main competitors and comparable companies include Monte Rosa Therapeutics (GLUE), Aktis Oncology (AKTS), Novavax (NVAX), Immatics (IMTX), and Vor Biopharma (VOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neoleukin Therapeutics compare to Monte Rosa Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Monte Rosa Therapeutics has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Monte Rosa Therapeutics	$123.67M	10.69	-$38.63M	-$1.76	N/A

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

In the previous week, Monte Rosa Therapeutics had 6 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for Monte Rosa Therapeutics and 0 mentions for Neoleukin Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.06 beat Neoleukin Therapeutics' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Monte Rosa Therapeutics	Neutral

Monte Rosa Therapeutics has a consensus price target of $28.50, suggesting a potential upside of 83.87%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Neoleukin Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Neoleukin Therapeutics' return on equity of -37.22% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Monte Rosa Therapeutics beats Neoleukin Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Aktis Oncology?

Neoleukin Therapeutics (NASDAQ:NLTX) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 3.3% of Aktis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neoleukin Therapeutics has higher earnings, but lower revenue than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Aktis Oncology	$6.50M	204.81	-$63.73M	-$0.38	N/A

Aktis Oncology has a consensus price target of $34.60, indicating a potential upside of 38.79%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Aktis Oncology	N/A	N/A	N/A

In the previous week, Aktis Oncology had 7 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 7 mentions for Aktis Oncology and 0 mentions for Neoleukin Therapeutics. Aktis Oncology's average media sentiment score of 0.98 beat Neoleukin Therapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Aktis Oncology	Positive

Summary

Aktis Oncology beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Novavax?

Novavax (NASDAQ:NVAX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Novavax had 7 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 7 mentions for Novavax and 0 mentions for Neoleukin Therapeutics. Novavax's average media sentiment score of 0.34 beat Neoleukin Therapeutics' score of 0.00 indicating that Novavax is being referred to more favorably in the media.

Company	Overall Sentiment
Novavax	Neutral
Neoleukin Therapeutics	Neutral

Novavax presently has a consensus price target of $13.00, indicating a potential upside of 61.49%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Novavax has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.18	$440.30M	-$1.52	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Novavax has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Neoleukin Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

Novavax beats Neoleukin Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Immatics had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Immatics and 0 mentions for Neoleukin Therapeutics. Immatics' average media sentiment score of 0.94 beat Neoleukin Therapeutics' score of 0.00 indicating that Immatics is being referred to more favorably in the media.

Company	Overall Sentiment
Immatics	Positive
Neoleukin Therapeutics	Neutral

Neoleukin Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Neoleukin Therapeutics' return on equity of -37.22% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Neoleukin Therapeutics has lower revenue, but higher earnings than Immatics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	23.18	-$222.26M	-$1.99	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

64.4% of Immatics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immatics presently has a consensus target price of $20.80, indicating a potential upside of 120.34%. Given Immatics' stronger consensus rating and higher possible upside, analysts clearly believe Immatics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Immatics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Summary

Immatics beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Vor Biopharma?

Neoleukin Therapeutics (NASDAQ:NLTX) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

In the previous week, Vor Biopharma had 25 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 25 mentions for Vor Biopharma and 0 mentions for Neoleukin Therapeutics. Vor Biopharma's average media sentiment score of 0.22 beat Neoleukin Therapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Vor Biopharma	Neutral

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Vor Biopharma's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Vor Biopharma	N/A	N/A	N/A

Vor Biopharma has a consensus price target of $43.38, suggesting a potential upside of 88.34%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Vor Biopharma beats Neoleukin Therapeutics on 10 of the 11 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NLTX vs. The Competition

Export

Metric	Neoleukin Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$334.85M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-11.46	10.67	269.06	25.28
Price / Sales	N/A	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	3.22	16.78	12.91	6.24
Net Income	-$57.56M	-$13.32M	$3.45B	$347.60M
7 Day Performance	0.08%	1.74%	1.12%	1.07%
1 Month Performance	-7.02%	1.60%	1.79%	1.03%
1 Year Performance	68.78%	56.43%	67.69%	20.77%

Neoleukin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NLTX Neoleukin Therapeutics	N/A	$35.63 -3.7%	N/A	+92.4%	$334.85M	N/A	N/A	90	High Trading Volume
GLUE Monte Rosa Therapeutics	2.8148 of 5 stars	$15.95 +1.2%	$28.50 +78.7%	+256.8%	$1.34B	$123.67M	N/A	90	Analyst Downgrade
AKTS Aktis Oncology	3.0643 of 5 stars	$24.00 -3.1%	$34.60 +44.2%	N/A	$1.32B	$6.50M	N/A	76	News Coverage Earnings Report
NVAX Novavax	1.6589 of 5 stars	$7.96 +0.1%	$13.00 +63.3%	-8.0%	$1.31B	$1.12B	N/A	1,990
IMTX Immatics	2.2669 of 5 stars	$9.71 -0.4%	$20.80 +114.2%	+57.2%	$1.31B	$54.60M	N/A	260

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NLTX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. GLUE, AKTS, NVAX, IMTX, and VOR

How does Neoleukin Therapeutics compare to Monte Rosa Therapeutics?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Summary

How does Neoleukin Therapeutics compare to Novavax?

Summary

How does Neoleukin Therapeutics compare to Immatics?

Summary

How does Neoleukin Therapeutics compare to Vor Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. GLUE, AKTS, NVAX, IMTX, and VOR

How does Neoleukin Therapeutics compare to Monte Rosa Therapeutics?

Which has stronger valuation and earnings, NLTX or GLUE?

Which has more volatility and risk, NLTX or GLUE?

Does the media refer more to NLTX or GLUE?

Do analysts recommend NLTX or GLUE?

Is NLTX or GLUE more profitable?

Do institutionals and insiders hold more shares of NLTX or GLUE?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Do insiders and institutionals have more ownership in NLTX or AKTS?

Which has preferable earnings and valuation, NLTX or AKTS?

Do analysts recommend NLTX or AKTS?

Is NLTX or AKTS more profitable?

Does the media favor NLTX or AKTS?

Summary

How does Neoleukin Therapeutics compare to Novavax?

Do institutionals & insiders have more ownership in NVAX or NLTX?

Does the media prefer NVAX or NLTX?

Do analysts prefer NVAX or NLTX?

Which has higher earnings & valuation, NVAX or NLTX?

Which has more risk & volatility, NVAX or NLTX?

Is NVAX or NLTX more profitable?

Summary

How does Neoleukin Therapeutics compare to Immatics?

Does the media prefer IMTX or NLTX?

Is IMTX or NLTX more profitable?

Which has preferable valuation & earnings, IMTX or NLTX?

Do institutionals and insiders have more ownership in IMTX or NLTX?

Do analysts recommend IMTX or NLTX?

Which has more volatility and risk, IMTX or NLTX?

Summary

How does Neoleukin Therapeutics compare to Vor Biopharma?

Does the media favor NLTX or VOR?

Do institutionals & insiders hold more shares of NLTX or VOR?

Which has more risk and volatility, NLTX or VOR?

Which has higher earnings & valuation, NLTX or VOR?

Is NLTX or VOR more profitable?

Do analysts recommend NLTX or VOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools